Conestoga Capital Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Descartes Systems
DSGX
|
+$16.6M |
| 2 |
WD-40
WDFC
|
+$14.4M |
| 3 |
JBTM
JBT Marel
JBTM
|
+$9.67M |
| 4 |
LeMaitre Vascular
LMAT
|
+$9.1M |
| 5 |
Bio-Techne
TECH
|
+$8.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VASC
Vascular Solutions Inc
VASC
|
+$43.7M |
| 2 |
ABAX
Abaxis Inc
ABAX
|
+$11.4M |
| 3 |
iRadimed
IRMD
|
+$5.6M |
| 4 |
NVE Corp
NVEC
|
+$3.6M |
| 5 |
Mesa Laboratories
MLAB
|
+$712K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.02% |
| 2 | Industrials | 23.76% |
| 3 | Technology | 21.88% |
| 4 | Consumer Discretionary | 7.35% |
| 5 | Materials | 5.31% |
Similar funds
Conestoga Capital Advisors's Q1 2017 Portfolio in Review
As of Q1 2017, Conestoga Capital Advisors held 122 positions worth $1.65B, up 10% from $1.5B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Conestoga Capital Advisors deployed $78.5M of net new capital in Q1 2017, opening 5 new positions and adding to 60 existing holdings. Its largest new stake was LeMaitre Vascular: 387,690 shares worth $9.55M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 27% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was NVE Corp, an estimated $3.6M trimmed.
- Conestoga Capital Advisors's largest Q1 2017 buy was LeMaitre Vascular: 387,690 shares worth $9.55M.
- Conestoga Capital Advisors added most to Descartes Systems in Q1 2017, an estimated $16.6M increase.
- Conestoga Capital Advisors's biggest Q1 2017 reduction was NVE Corp, cutting an estimated $3.6M.
- Conestoga Capital Advisors fully exited Vascular Solutions Inc in Q1 2017, selling an estimated $43.7M.
- Conestoga Capital Advisors's ten largest holdings make up 30% of its $1.65B portfolio in Q1 2017.
- Conestoga Capital Advisors opened 5 new positions and closed 9 in Q1 2017.
- Conestoga Capital Advisors's portfolio value rose 10% quarter-over-quarter to $1.65B.
Based on Conestoga Capital Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.